26.97
2.71 (11.17%)
| Penutupan Terdahulu | 24.26 |
| Buka | 24.95 |
| Jumlah Dagangan | 912,989 |
| Purata Dagangan (3B) | 846,525 |
| Modal Pasaran | 2,092,659,584 |
| Harga / Jualan (P/S) | 650.22 |
| Harga / Buku (P/B) | 8.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| EPS Cair (TTM) | -3.06 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.06% |
| Nisbah Semasa (MRQ) | 8.06 |
| Aliran Tunai Operasi (OCF TTM) | -169.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -68.57 M |
| Pulangan Atas Aset (ROA TTM) | -25.34% |
| Pulangan Atas Ekuiti (ROE TTM) | -65.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Spyre Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.10 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.71% |
| % Dimiliki oleh Institusi | 106.07% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (BTIG, 159.55%) | Beli |
| Median | 64.00 (137.30%) | |
| Rendah | 53.00 (Mizuho, 96.52%) | Beli |
| Purata | 62.75 (132.67%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 32.11 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 16 Jan 2026 | 70.00 (159.55%) | Beli | 33.24 |
| Mizuho | 18 Dec 2025 | 53.00 (96.51%) | Beli | 33.47 |
| Citigroup | 17 Dec 2025 | 64.00 (137.30%) | Beli | 33.06 |
| Jones Trading | 01 Dec 2025 | 64.00 (137.30%) | Beli | 28.66 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 Jan 2026 | Pengumuman | Spyre Therapeutics Announces Grants of Inducement Awards |
| 12 Jan 2026 | Pengumuman | Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 |
| 08 Jan 2026 | Pengumuman | Spyre Therapeutics Announces Grants of Inducement Awards |
| 05 Dec 2025 | Pengumuman | Spyre Therapeutics Announces Grants of Inducement Awards |
| 07 Nov 2025 | Pengumuman | Spyre Therapeutics Announces Grants of Inducement Awards |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |